A Randomized, Open-label, Phase 2 Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
Latest Information Update: 19 Aug 2020
At a glance
- Drugs Tucidinostat (Primary) ; Camrelizumab; Decitabine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 Aug 2020 New trial record